Adding the anti-CD38 monoclonal antibody daratumumab to the standard backbone multiple myeloma (MM) regimen of lenalidomide-dexamethasone substantially improved response rates and progression-free survival (PFS) in previously treated patients with relapsed/refractory disease during the Phase III POLLUX trial.
During this international, open-label trial, the three-drug combination was associated with a 63% reduced risk for progression or death versus lenalidomide (Revlimid, Celgene) and